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It is now clear that the presence of obesity substantially increases the risk of related 
co-morbidities such as insulin resistance, diabetes, dyslipidemia, hypertension and 
others. The objective of this study was to measure adiponectin, insulin hormones, and 
homocysteine concentrations in obese Egyptian women before and after diet therapy 
that consisted of a hypo-caloric regimen supplemented with a formula rich in dietary 
fiber, folate and betaine. This study investigated serum adiponectin, insulin, 
homocysteine, lipid profiles, haemoglobin and homeostatic model assessment 
(HOMA) value in twenty eight volunteer obese women, whose mean age was 
47.86±2.18 years and body mass index (BMI) was 34.10± 0.95 kg/m2. The studied 
period was 8 weeks divided into two phases, 1 and 2 of 4 weeks each. In the first 
phase, the women consumed a hypo-caloric diet (900-1000 Kcal/day) plus the 
supplement made from highly extracted wheat (82%) composited with ground peanuts 
at a 50:50 ratio, prepared as cookies of; 20 g each. Two cookies were consumed at 
breakfast and one at dinner, to replace the bread carbohydrate content. In the second 
phase, the same subjects consumed only the hypo-caloric diet. Results showed that 
fasting serum glucose, insulin, homocysteine concentrations and HOMA values were 
reduced significantly (P<0.01) at the end of the 1st phase, while adiponectin hormone 
was slightly decreased (1.3%). Homocysteine concentration increased significantly 
(P<0.05) at the end of the 2nd phase, while the other parameters showed only 
numerical increase. Adiponectin was positively correlated with high density 
lipoprotein cholesterol (HDL-C) at P<0.01 at all phases of the study, while insulin and 
HOMA were negatively associated at the start of the study.  Homocysteine was 
positively correlated (P<0.05 and P<0.01) with cholesterol, low density lipoprotein 
cholesterol (LDL-C) and glucose at the basal test, than with systolic blood pressure 
(SBP), diastolic blood pressure (DBP), and HOMA (P<0.01) at the end of the 1st 
phase. In conclusion, the weight reducing diet supplemented with the dietary fiber 
rich formula in the short-term might have a beneficial effect on body weight, insulin 
and homocysteine. Adiponectin showed minor changes, but its role against 
dyslipidemia could be suggested. 
 









Insulin resistance is defined as a subnormal response to both endogenous and 
exogenous insulin [1]. It is characterised by a decreased sensitivity of the target tissue 
to the action of insulin, by elevated blood glucose concentration, and increased 
hepatic production of atherogenic lipids [2]. Adiponectin has now been added on the 
list as a new player in the field of obesity-related insulin resistance and 
atherosclerosis. Adiponectin gene expression in white adipose tissue is decreased by 
obesity, glucocorticoids, β-adrenergic, cold exposure, adrenalectomy and insulin like 
growth factor 1(IGF-1) [3].  
 
The main mechanism of action of adiponectin is directed to a protective role against 
atherogenic and insulin resistance processes [4]. Adiponectin is an adipokine that 
exerts a potent insulin-sensitizing effect by binding to its receptors (AdipoR) such as 
AdipoR1 and AdipoR2, leading to activation of AMP-activated protein kinase, PPAR-
α and presumably some other unknown signalling pathway [5]. 
 
On the other hand, homocysteine is an important risk factor for cardiovascular 
disease. There is a growing amount of clinical evidence indicating that mild to 
moderate fasting hyperhomocysteinemia is an independent risk factor for 
atherosclerosis [6]. A study carried out on 149 overweight and obese volunteers 
showed a significantly higher level of serum homocysteine in the overweight subjects. 
They found that serum folic acid in the overweight and obese was significantly lower 
than in the control subjects [7]. 
 
Homocysteine is controlled both by mutations in its regulating enzymes and the B 
vitamins; folic acid, B12 and B6 (pyridoxine). Furthermore, some evidence suggests an 
increase in plasma homocysteine concomitant to weight loss, apparently due to a 
decrease in the regulatory B vitamins [8]. In this context, nut is a rich source of 
vitamins, minerals, antioxidants and plant proteins which could be also beneficial [9]. 
It has been also reported that egg yolks are the richest source of choline, followed by 
soybeans, spinach, beet and that whole wheat products are primary sources of betaine; 
the metabolite of choline [10]. Choline and betaine work together in the cellular 
process of methylation, which is not only responsible for removal of homocysteine, 
but is involved in turning off the promoter regions of genes involved in inflammation 
[11].  
 
The aim of this work was to highlight the impact of a fiber and vitamin B rich natural 
formula supplementing a low calorie balanced restrictive diet for reducing  weight, on 
the course of obesity, by measuring both positive and negative influences exemplified 
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Twenty eight obese women participated in this study which lasted eight weeks. They 
were recruited from the National Research centre, Cairo Egypt as volunteers. The 
protocol for the study was approved by the National Research Center Ethics 
Committee. In addition, a written informed consent was obtained from each 
participant to be included in the study. The subjects involved in the study had a mean 
age of 47.86±2.18 years, and mean BMI of 34.10±0.95 kg/m². The study was divided 
into two phases of four weeks each. During the first phase (phase1), they followed a 
low calorie balanced diet, accompanied by the designed cookies, consumed as two 
cookies with breakfast and one with dinner to replace bread. The hypocaloric diet 
provided an average 48.3 g protein, 139 g carbohydrate, 29 g fat and 8 g fiber, which 
supply about 1000 kcal/day. The aim of the supplement was to enrich the hypocaloric 
regimen with a formula containing considerable amounts of vitamins, minerals and 
fiber producing a satiating effect. In addition, the highly extracted wheat flour 
contains betaine and choline, 747µg/g and 76µg/g, respectively [12]. In the second 
phase (phase 2), the same volunteers continued to follow only the same low calorie 
balanced diet, whereas the supplement was replaced by a portion of Egyptian bread 
that supplied equal amounts of calories, aiming to evaluate the health effect of the 
supplement on the same patients.   
 
All individuals were subjected to thorough clinical examination at the beginning of 
the study. Relevant anthropometric measurements were recorded including weight, 
height and waist circumference using standard methods [13].  Body mass index (BMI) 
(weight in kg/height² in meter), fat free mass (FFM) and fat mass (FM) were 
calculated [14]. Blood pressure was measured, using a mercury sphygmomanometer. 
 
Blood sampling and biochemical analysis 
Fasting blood samples were obtained from the women before the dietary regimen at 
baseline, after the first 4 weeks (phase 1) and lastly at the end of the following 4 
weeks (phase2). The blood samples were drawn in the morning after twelve hours 
fasting. Haemoglobin concentration was measured in the fresh samples by using the 
cyanomethaemoglobin method [15]. The rest of the blood samples were allowed to 
clot, centrifuged and sera separated. Blood glucose was determined in fresh sera using 
the oxide peroxidase method [16]. The remaining sera were divided into aliquots and 
stored in eppindorf tubes at –20 oC until used for further analysis. Serum total 
cholesterol, HDL-C and triglycerides were done using: cholesterol proceed No 1010, 
Stanbio HDL-C proceed No 0599, and stanbio Liquicolor triglycerides proceed No 
2100, respectively. Friedewald formula was used to calculate LDL-C; LDL-C= [Total 
cholesterol] – [HDL-C] – [Triglyceride/5]. Serum Insulin was measured using Insulin 
Accu Bind ELISA Microwells Product Code: 2425-300 Monobind, INC,Costa Mesa, 
CA 92627 (USA) . Serum Adiponectin was measured using AviBion Human 
Adiponectin (Acrp30) ELISA Kit: ADIP025. Orgenium Laboratories. Viikinkaari 6. 
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Axis Homocysteine EIA, distributed by IBL-Hamburg, Germany. IBL-Cat. - No.: AX 
513 01.  
 
Homeostatic model assessment (HOMA) was calculated using the equation:  
 




The designed supplement formula in this study was prepared from highly extracted 
wheat flour (82%) and ground peanuts mixed in equal amounts. The formula was 
made into cookies by adding vegetable oil, yeast (Saccharomyces cerevisiae), water 
and cinnamon powder as a flavour. Each cookie weighed 20 g (Table 1). 
 
Preparation of the cookie 
Peanuts, whole wheat flour and the other ingredients were obtained from the local 
market (Cairo, Egypt). Peanuts were decorticated and then ground electrically in a 
mill (Wiley, model 4, England). The formula was made by mixing 460 g ground 
peanuts, 460 g whole wheat flour, 25 g corn oil, 25 g salt, 25g yeast and 5g cinnamon 
powder. Tap water (200 ml), was added and the blend kneaded using an electric mixer 
(Moulinex, France). The dough formed was allowed to ferment for 45 minutes, was 
cut into small pieces, put in cookie models and baked thermoelectrically in an oven at 
180 ◦C for 20 minutes. After baking, the weight of each cookie was recorded, and 
each 3 were tightly wrapped and sealed in plastic food wrap.  
 
Chemical analysis of the cookie supplement  
Chemical analysis of the cookie was undertaken for macronutrients; including protein, 
fat and carbohydrate; using AOAC International methods: 668,931, 933 and 937, 
respectively [18]. Dietary fiber determination was done using AOAC International 
method: 985.29 [19]. Total energy was determined by calculation, taking in 
consideration that 3.6g crude fiber was included in the carbohydrate value, ( protein 
energy= 42.4, carbohydrate energy=121.6, and fat energy=109.8). Micronutrients 
including: calcium, iron, magnesium, zinc and folate were calculated using World 
Food Dietary Assessment System (WFDAS), 1995, University of California, UNU/ 
FAO [20]. 
 
Statistical analysis  
All values were expressed as mean± SE, two tailed student t-test was used to compare 
the two groups. Correlation between the different parameters was tested by Pearson 
test. P values <0.05 were considered statistically significant. SPSS window software 










Chemical composition of the cookie supplement  
The data showed a high content of protein (10.6 g/100 g) and high dietary fiber 
content (6 g/100 g). The formula contains considerable amounts of folate (66.4 
mg/100 g), magnesium (72 mg/100 g) and iron (2.3 mg/100 g) (Table 2). 
 
Characteristic anthropometric parameters and blood pressure of the studied 
obese women during the two periods of dietary therapy 
Comparison between the means of all the measured parameters showed a highly 
significant decrease (P<0.01) at the end of the two phases. Significant reduction in 
diastolic blood pressure (DBP) at P<0.05 was only recorded after the end of phase 1 
(Table 3). 
 
Haemoglobin and serum lipid profile 
Significant increase was detected in the mean level of haemoglobin at the end of 
phase 1. Serum total cholesterol (T. cholesterol) concentration decreased by 5.28% 
and 3.37% after the end of phase 1, and phase 2, respectively. Significant elevation in 
the level of serum HDL-C (12.74%) was detected at the end of phase 1, while its level 
decreased significantly by 9.7% at the end of phase 2. The level of LDL-C and 
triglycerides decreased significantly at p<0.05 and at p <0.01 respectively, after the 
end of phase 1 only. Cardiovascular risk factor decreased significantly by (14.43%) in 
phase 1, while it increased significantly by (5.8%) at the end of phase 2, when 
compared to phase 1 (Table 4). 
 
Serum glucose, insulin, adiponectin and homocysteine concentrations, and 
HOMA values  
The mean values of all the parameters showed significant reduction (P<0.01) at the 
end of phase 1, while adiponectin hormone showed slight decrease by (1.3%). 
Homocysteine concentration increased significantly (P<0.05) at the end of phase 2, 
compared to phase 1. All other parameters showed slight numerical increase at the 
end of phase 2 (Table 5). 
 
Relation between adiponectin, homocysteine, different biochemical parameters 
and blood pressure 
Adiponectin showed a significant positive correlation coefficient at P<0.01 with the 
HDL-C concentration at all times of the investigations. Insulin, and HOMA 
negatively correlated with adiponectin, and the correlations were significant only at 
the start of the study. At the end of phase 2 the adiponectin level also correlated 
positively with the T. Cholesterol and fasting blood glucose. Homocysteine showed a 
significant positive correlation with cholesterol, LDL-C, and fasting glucose at 











The discovery of adiponectin undoubtedly represents an  important step to further 
understand the mechanism of obesity that induces insulin resistance and 
atherosclerosis [21]. Measurement of the adiponectin concentration in obese Egyptian 
women in this study showed that the mean serum concentration of the adiponectin 
ranged from 12.18±0.45 to 12.07±0.45 µg/ml, with little difference between the basal 
level and the other levels recorded after the two phases of dieting. This study was a 
short period type, yet the percent reduction in the body mass index (BMI) and fat 
mass (FM) values were satisfactory regarding the time of the experiment. At the end 
of the two dieting phases, however the women were still considered to be obese and 
still had relatively high BMI (33.2±0.89 versus 32.3±0.88 Kg/m2) and FM 
(34.36±2.07 versus 32.78±1.44), which might be the reason for the little changes 
observed in the adiponectin concentration. In this respect, a recent study stated that 
serum adiponectin values displayed a threshold effect with increasing obesity beyond 
which concentration did not significantly decline [22]. In addition, another study 
found that adiponectin gene expression and plasma levels were not modified during 
calorie restriction [23]. However,   the data in this study showed an intragroup 
variation in the adiponectin levels between the obese women before and during 
dieting. The range was 6.64 to 14.54 µg/ml at the basal level, 7.29 to 14.77 µg/ml at 
the end of the first phase,  and 6.75 to 14.76 µg/ml at the end of the study. These 
results are in agreement with another study that reported marked variation in 
adiponectin concentrations even among obese subjects, whose levels ranged from 1.9 
to  17 µg/ml [24].  As a result of this variation, adiponectin showed a positive 
correlation with HDL-C at the basal level and at the end of the two phases of dieting. 
In contrast, negative association were found between the adiponectin level, and each 
of insulin and HOMA, which may further support the concept of its protective role 
against arteriosclerosis and insulin resistance [4]. Our study could therefore suggest 
that since adiponectin is a natural hormone readily secreted by the body, and which 
actively participates in the web of controlling loops in an attempt to optimize the 
physiology of the internal environment towards normality, the small variations in the 
mean values reflect that the subjects were still obese, and that the positive correlations 
with HDL-C and the negative ones with insulin and HOMA would be conducive 
towards healthier outcomes. 
 
Obesity affects blood lipids and homocysteine levels negatively. The early detection 
and control of obesity and the management of dyslipidemia and homocysteine levels 
may help to reduce the risk of cardiovascular disease in the young population [25]. 
Hyperhomocysteinemia promotes atherosclerosis and is most commonly carried out 
by B-vitamin deficiencies; especially folic acid, B6 and B12, genetic disorders, certain 
drugs and renal impairment. Elevated homocysteine promotes atherosclerosis through 
increased oxidative stress, impaired endothelial function, and induction of thrombosis 
that increase the risk of cardiovascular disease by two folds and the risk of 
cerebrovascular disease to a lesser degree [26]. In addition,  it has been reported that 
homocysteine thiolactone impairs insulin signalled by a mechanism involving 
oxidative stress, leading to a defect in insulin action [27]. The results of this study are 
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µmol/L),  accompanied by   high values of both insulin concentration and the 
calculated HOMA value were found in the obese women. In the meantime,  
homocysteine showed a significant positive correlation with cholesterol, LDL-c and 
glucose concentration, which may increase the risk of atherosclerosis and diabetes 
mellitus. After the first phase of the dietary therapy, homocysteine concentration 
decreased significantly to reach 11.8±1.04 µmol/L which was accompanied by a 
significant decrease in the levels, and a significant positive correlation with insulin 
and HOMA values. In addition, it showed the same association with SBP and DBP. 
However in the second phase of dietary therapy, it was noticed that homocysteine, 
insulin and HOMA mean values increased significantly. Homocysteine mean value 
reached 13.4±1.04 µmol/L, yet optimal plasma homocysteine is defined as the level 
below 11.7µmol/L, and values above 12.0 µmol/L have consistently been associated 
with vascular disease [28]. The results obtained in this study could be explained by 
the protective high level of vitamin B in the peanut supplement used in the first period 
of the diet therapy. It has been demonstrated that the regular peanut consumers had a 
better quality diet -having higher contents of vitamin E, folate, magnesium, zinc and 
iron; and also that low B vitamins may follow a weight-reducing regimen [29]. 
Consequently, an increase in plasma homocysteine is anticipated and can be 
prevented by vitamin supplementation [30]. In addition, the high betaine content of 
the wheat used in the supplement formula may also have a lowering effect on the 
serum concentration of homocysteine. It has been reported that betaine is also 




The low calorie regimen supplemented by the weight reducing formula rich in dietary 
fiber, folate and betaine; and which has a low glycemic index proved to  have a 
beneficial effect on body weight, serum levels of insulin and  homocysteine; those  
play an important role in the process of the development of both atherosclerosis and 
insulin resistance. Equally important is that in spite of adiponectin hormone showing 
minor changes, its protective role against these two pathological conditions should be 
considered. This was a short term effect and a similar study should be recommended 
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Table 1: Ingredients of the cookie supplement in grams (g/ Kg) 
 
























Table 2:  Chemical composition of the supplement formula (/100 g) 
 
Macronutrients Amount Micronutrients* Amount 
    
Energy (kcal) 274.0 Folate (mg) 66.4 
Protein (g) 10.6 Calcium (mg) 32.8 
Carbohydrate (g)  34 Magnesium (mg) 72 
Fat (g) 12.2 Iron (mg) 2.3 
Dietary fiber (g) 6.0 Zinc (mg) 1.6 
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Table 3: Characteristic anthropometric parameters and blood pressure of the 
studied obese women during the two phases of dietary therapy 
 
Parameters 




























































Values are expressed as mean± standard error (SE) 
BMI: Body Mass Index, FFM: Fat Free Mass, FM: Fat Mass, SBP: Systolic Blood 
Pressure, DBP: Diastolic Blood Pressure 
 ** Significant at P≤0.01 
  a Baseline vs. phase 1  
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Table 4: Haemoglobin and serum lipid profiles among obese women during the 
































T.Cholesterol (mg/dl) 217.25±6.06 205.79±6.65 198.85±8.55 -5.28 -3.37 
HDL-C(mg/dl) 55.12±2.00 62.14±2.43 56.11±2.39 +12.74**a -9.7**b 
LDL-C(mg/dl) 145.11±5.87 129.37±6.61 128.84±7.84 -10.85*a -0.41 
Triglycerides(mg/dl) 85.12±5.58 71.43±3.87 69.39±3.79 -16.08**a -2.8 
Risk factor 
(T.cholesterol/HDL-C) 
4.02±0.14 3.44±0.16 3.64±0.17 -14.43**a +5.8*b 
 
Values are expressed as mean± standard error (SE) 
T.Cholesterol: Total Cholesterol, HDL-C: High Density Lipoprotein-Cholesterol, LDL-C: 
Low Density Lipoprotein-Cholesterol. 
* Significant at P< 0.05                                                 ** Significant at P<0.01  
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Table 5: Fasting glucose, insulin, adiponectin hormones, homocysteine and 






                          Periods 
 
















































Values are expressed as mean± standard error (SE) 
FBG: Fasting Blood Glucose, HOMA: Homeostatic Model Assessment. 
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Table 6: Correlation coefficient between adiponectin, homocysteine, and different 




































LDL-C 0.048 0.119 0.203 0.461* -0.351 -0.228 
HDL-C 0.602** 0.574** 0.776** -0.066 0.072 0.049 
FBG 0.325 0.340 0.588** 0.582** 0.246 -0.017 
Insulin -0.569** -0.179 -0.348 -0.062 0.364 0.337 
HOMA -0.533** -0.138 -0.196 -0.020 0.414* 0.355 
SBP -0.148 0.272 0.352 0.121 0.531** 0.162 
DBP 0.298 0.205 0.336 -0.012 0.510** 0.244 
 
T.Cholesterol: Total Cholesterol, LDL-C: Low Density Lipoprotein-Cholesterol, HDL-C: 
High Density Lipoprotein-Cholesterol, FBG: Fasting Blood Glucose, HOMA: Homeostatic 
Model Assessment, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure. 
** Correlation is significant at the 0.01 level (2-tailed). 
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